Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Final Diagnosis and Treatment Result of Metastatic Cervical Carcinoma of Unknown Primary

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2005 by National Taiwan University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00302588
First received: March 12, 2006
Last updated: NA
Last verified: December 2005
History: No changes posted

March 12, 2006
March 12, 2006
January 2006
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
The Final Diagnosis and Treatment Result of Metastatic Cervical Carcinoma of Unknown Primary
Not Provided

Investigate the final diagnosis and treatment result of metastatic cervical carcinoma of unknown primary

Carcinoma of unknown primary (CUP) is defined as biopsy-proven metastasis of an epithelial malignancy in the absence of an identifiable primary site after complete history and physical examination, basic laboratory studies, chest X-ray and additional directed studies indicated by positive findings during the initial work-up. It is characterized by its slow local development and its high metastatic potential.1,2 Patients with CUP represent 4–10% of all new cancer patients.3,4 The presenting sites of metastasis identified pathologically, radiographically or by physical examination were found most frequently in the lymph nodes (37.1%), followed by the liver, bone, lung, pleura/pleural space, brain, peritoneum, adrenal and skin. Of the lymph nodes of metastasis, the supraclavicular cervical area is the leading site (31.3%), followed by the mediastinum, axilla, retroperitonium, and inguina.5 The incidence of metastatic cervical CUP (MCCUP) varies between 2% and 9% of all head and neck cancers.6-8 The level of cervical metastatic involvement may give some clue as to the likely primary site. A submandibular mass (level I) would most commonly be related to a primary in the oral cavity or skin. Level II nodes, including the jugulodigastric node, may point to a primary in the oral cavity, oropharynx, or supraglottic larynx. Tumours of the nasopharynx generally spread to level II or the posterior triangle, as well as retropharyngeal nodes. Middle and lower jugular nodes (levels III and IV) are more likely related to a laryngeal or hypopharyngeal cancer. Metastatic disease restricted to the supraclavicular region is often due to an infraclavicular primary site.9 The prognosis is different according to the involved lymph node level and possible primary site. Modern cancer management relies heavily on recognition of the primary tumor; thus the absence of a primary site poses major diagnostic and therapeutic problems. The patient benefits from identification of the initial tumor site because postoperative irradiation ports may be reduced and because surveillance for recurrence may be improved.10 In order to identify the likely primary site of MCCUP and compare the prognoses of known and unknown primary groups, we report the results according to the different levels of metastatic cervical lymph nodes.

Observational
Allocation: Random Sample
Observational Model: Natural History
Time Perspective: Longitudinal
Not Provided
Not Provided
Not Provided
Not Provided
Metastasis Cervical Lymph Nodes of Unknown Primary Carcinoma
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
February 2006
Not Provided

Inclusion Criteria:

  • cases of metastatic cervical carcinoma of unknown primary

Exclusion Criteria:

-

Both
20 Years to 75 Years
No
Contact: Ching-Ting Tan, MD, PhD 886-2-23123456 ext 5222 christin@ha.mc.ntu.edu.tw
Taiwan
 
NCT00302588
9461701257
Not Provided
Not Provided
National Taiwan University Hospital
Not Provided
Principal Investigator: Ching-Ting Tan, MD, PhD National Taiwan University Hospital
National Taiwan University Hospital
December 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP